May 28, 2019 05:42 AM EDT
R&D
FDA+

FDA hits the red light on piv­otal tri­als at Newron, de­mand­ing new stud­ies af­ter rais­ing safe­ty con­cerns

John Carroll

Editor & Founder

Two years af­ter Newron $NWRN came up with a mixed set of Phase IIa da­ta for its an­tipsy­chot­ic eve­namide, the FDA is halt­ing their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times